2015_Notebook - The Massachusetts Technology Transfer Center

Transcription

June 2, 2015
Welcome to Massachusetts Life Sciences Innovation Day!
Once again, it is our pleasure to bring together major organizations throughout the state to create a high-energy, hands-on event which includes scientific leaders and business experts to
mingle with innovators, post-docs, professors, entrepreneurs, and venture capitalists. This is the
biggest day for life sciences startups and innovation in the Commonwealth of Massachusetts.
This year’s theme is “Weathering Healthcare Climate Change.” Our speakers and panelists will
consider how the environment, in which new inventions are commercialized and start-ups are
created, is constantly and radically changing; and how do you make sure that your commercialization plan is robust enough to weather all of the changes that may impact your plan. Our
speakers and panelists have years of experience and represent a wide range of technologies
and inventions – they will talk about how they have survived past changes and hope to live
through future ones. They are presidents, CEOs, investors and consultants of leading companies and institutions throughout the area. We hope you find their discussions thought provoking.
The Poster Competition includes some of the greatest and newest ideas that could impact medicine in the future. Remember to invest your “MALSI dollars” in your favorite posters – it could
help the inventors raise their first round of investment! Winners will be announced by State
Senator Karen Spilka during our ever popular evening reception. The reception will also be attended by many additional life sciences CEOs who will join us late afternoon to help judge the
poster finalists. Don’t miss the opportunity to speak with them and discuss your projects.
We are particularly grateful to our Planning Committee for their help, support and entrepreneurial spirit in organizing this event. We would also like to thank all of our sponsors, particularly Pepper Hamilton LLP and the Massachusetts Life Sciences Center, our lead sponsors for this event.
All of our sponsors are as committed as we are to supporting the creation of new companies and
we are grateful to them all.
We hope you enjoy our flagship event of life sciences in Massachusetts, jointly and actively put
together by all the major organizations that are involved in starting and supporting the life sciences start-up ecosystem in the Commonwealth.
Dr. Abigail A. Barrow
Chair MALSI
Director, MTTC
Interim Executive Director, OTCV-UMass
8th Annual
Massachusetts Life Sciences Innovation Day
Table of Contents
Floor Plan – Harvard Club of Boston................................................................................................iii
Conference Agenda ..............................................................................................................................iv
Speaker Biographies...............................................................................................................................6
MALSI Day Planning Committee.................................................................................................... 23
Sponsors, Affiliates & Organizers.................................................................................................... 25
Gold Sponsors.................................................................................................................................................................26
Silver Sponsors................................................................................................................................................................28
Conference Supporters................................................................................................................................................30
Organizers.........................................................................................................................................................................31
In association with ........................................................................................................................................................34
Poster Presenters.................................................................................................................................. 35
Innovators’ Marketplace Exhibitors................................................................................................ 42
Life Science Products and Services .........................................................................................................................42
Entrepreneurship Support..........................................................................................................................................42
Funding..............................................................................................................................................................................43
Professional Services.....................................................................................................................................................43
ii Floor Plan – Harvard Club of Boston
TIME
SESSION
Foyer Harvard Hall
Registration & Breakfast
8:00 AM
Harvard Hall
9:00 AM
Welcome by Conference Chair Abigail Barrow, Director, Massachusetts Technology Transfer Center
and by Massachusetts Life Science Center
9:10 AM
Opening Keynote
Mason (Skip) Irving III, Vice President, Stemnion, Inc, author of Impact 2020
9:40AM
Plenary Panel: Startups that got funded in the last 18 months
Panelists:
Patrick Anquetil, CEO & Co-Founder, Portal Instruments Inc.
Marcia Fournier, Founder & CEO, BIOARRAY Therapeutics Inc.
Geraldine Hamilton, President & CSO, Emulate
Ruben Salinas, President & CEO of Parsagen Diagnostics
Moderator:
Thomas Engellenner, Partner, Pepper Hamilton LLP
Harvard Foyer and Commonwealth Lounge on the 1st Floor
10:30AM
11:00 AM
NETWORKING BREAK / POSTER & STARTUP SHOWCASE
Massachusetts Room
Estabrooks Room
The Nuts and Bolts of what to do after you
have cashed your first investor check
If you build it will they come? Creating a
compelling value proposition for your idea
Panelists:
Panelists:
Jeff Behrens, President & CEO, Siamab
Therapeutics, Inc.
Richard Berenson, CEO, Thermalin Diabetes
Will Cowen, Managing Partner, Long River
Ventures
Eric Walters, CEO, Co-Founder & Director,
ONEighty C Technologies Corporation
Carl Berke, Partner, Partners HealthCare Innovation
Fund
Prem Das, Chief Research Business Development
Officer, Belfer Office for Dana-Farber Innovations
Aaron Sandoski, Co-founder & Managing Director,
Norwich Ventures
Josh Tolkoff, Partner, Ironwood Equity
Moderator:
Scott Samuels, Partner, Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C.
Moderator:
Richard Anders, Founder & Managing Director, Mass
Medical Angels
Harvard Hall
12:15 PM
Remarks by Katie Stebbins, Assistant Secretary of Innovation, Technology, and Entrepreneurship,
Massachusetts’ Executive Office of Housing and Economic Development
Lunch Keynote
Roger Tung, Co-Founder, President & CEO, Concert Pharmaceuticals
1:45 PM
Massachusetts Room
Estabrooks Room
Early risk reduction of your technology in the lab
Health policy and how its changing will shape
the life sciences sector
Panelists:
Bill Edelman, Chairman of the Board, Vitathreads LLC
Curtis Keith, CSO, Blavatnik Biomedical Accelerator at
Harvard University
Mark Ralph, Director, External Partnership Operations,
Boehringer Ingelheim
Kevin Scanlon, Founder & CEO, International
BioScience
Panelists:
Jonathan Fleming, Managing Partner, Oxford
Bioscience Partners
Michael Greeley, General Partner, Flare Capital
Partners
Laura Housman, Senior Vice President,
Molecular Health
Moderator:
Moderator:
Seth Taylor, CFO & CBO, Mass Innovation Labs
Edward Berger, Principal & Founder, Larchmont
Strategic Advisors
Harvard Foyer and Commonwealth Lounge on the 1st Floor
3:00PM
3:30PM
NETWORKING BREAK / POSTER & STARTUP SHOWCASE
Massachusetts Room
Estabrooks Room
Start-up lessons learned...the hard way
First financing for emerging companies
Panelists:
Panelists:
Denise Aronson, President & Founder, Safety Partners
Jeff Arnold, President, Arnold Strategies, LLC
Paulina Hill, Principal, Polaris Partners
Roger Kitterman, Executive Director, Boston
Biomedical Innovation Center
Darshana Zaveri, Partner, Catalyst Health
Ventures
Pravin Chaturvedi, Founder & Chairman, IndUS
Pharmaceuticals
Thomas Forest Farb, President, Thrive Bioscience, Inc.
John Tagliamonte, Chief Business Officer, Oxyrane
Moderator:
Roger Frechette, Partner & Co-founder, New England
PharmAssociates
Moderator:
Imran Nasrullah, Director, Innovation Sourcing,
Boehringer Ingelheim
Harvard Hall
5:00 PM
Reception / Innovators’ Marketplace
Poster Awards by Karen Spilka, State Senator, 2nd Middlesex and Norfolk district
8th Annual
Speaker Biographies
Richard Anders.........................................................................................................................................7
Patrick Anquetil........................................................................................................................................7
Jeff Arnold..................................................................................................................................................7
Denise Aronson........................................................................................................................................8
Abigail Barrow..........................................................................................................................................8
Richard Berenson.....................................................................................................................................9
Edward Berger....................................................................................................................................... 10
Carl Berke................................................................................................................................................. 10
Pravin Chaturvedi ................................................................................................................................ 11
Will Cowen.............................................................................................................................................. 11
Prem Das ................................................................................................................................................. 12
Bill Edelman ........................................................................................................................................... 12
Tomas Engellenner.............................................................................................................................. 13
Thomas Forest Farb.............................................................................................................................. 13
Jonathan Fleming................................................................................................................................. 14
Roger Frechette .................................................................................................................................... 14
Michael Greeley..................................................................................................................................... 15
Geraldine Hamilton............................................................................................................................. 15
Paulina Hill.............................................................................................................................................. 16
Laura Housman..................................................................................................................................... 16
Mason (Skip) Irving, III......................................................................................................................... 17
Curtis Keith............................................................................................................................................. 17
Roger Kitterman.................................................................................................................................... 18
Imran Nasrullah..................................................................................................................................... 18
Mark Ralph ............................................................................................................................................. 18
Scott Samuels........................................................................................................................................ 19
Aaron Sandoski..................................................................................................................................... 19
Kevin Scanlon........................................................................................................................................ 20
Katie Stebbins........................................................................................................................................ 20
John Tagliamonte ................................................................................................................................ 20
Seth Taylor............................................................................................................................................... 21
Josh Tolkoff............................................................................................................................................. 21
Roger Tung.............................................................................................................................................. 21
Eric Walters ............................................................................................................................................. 22
Darshana Zaveri.................................................................................................................................... 22
6 Biographies
June 2, 2015
Harvard Club of Boston
Speaker Biographies
Richard Anders
Founder & Managing Director, Mass Medical Angels
Richard Anders is a long-time entrepreneur. He founded the legal software publishing company Jurisoft,
which he sold to Lexis/Nexis, published newspapers including Boston Digital Industry and New York Digital
Industry and is currently managing director of Rubin/Anders Scientific, which places scientists as consultants
in patent projects. He served for many years as a member of the Institutional Review Board at the Dana Farber Cancer Center, and was a long-time trustee of the Museum of Science, where he currently is an overseer.
Richard founded and currently runs MA Medical Angels (MA2), one of the country’s leading angel groups
focused exclusively on life sciences. He founded the angel group Launchpad, the nationally renowned Science on Screen event at the Coolidge Corner Cinema, and was a founding trustee of the Massachusetts
Interactive Media Council. He is a board observer at Avaxia Biologics and Sialix and an overseer at the
Gardner Museum. Richard teaches medical device entrepreneurship at the Harvard/MIT HST program. He
is a graduate Summa Cum Laude in Mathematics from Harvard and holds a J.D. from Harvard Law School.
Patrick Anquetil
CEO, Portal Instruments, Inc.
Dr. Patrick Anquetil is the CEO at Portal Instruments, where he is leading the company from inception to its
first product. Patrick began his career as a science and nanotechnology equity research analyst at Susquehanna International Group. He subsequently co-founded SynapDx Corp. a medical diagnostic company
in the field of autism. He received a PhD in Bio-Instrumentation from MIT, an MBA from Harvard Business
School and a Master’s degree from the ETH in Zurich and the University of Tokyo. His work has appeared in
peer-reviewed publications as well as mainstream media such as MIT Technology Review, Wired Magazine,
PBS, and CNBC.
Jeff Arnold
President, Arnold Strategies, LLC
Mr. Arnold is the president of Arnold Strategies, LLC, a strategic advisor to early and growth stage CEO’s,
and an angel investor with Mass. Med. Angels and Boston Harbor Angels. As an angel investor, Mr. Arnold,
has invested in, among others, SmartCells (sold to Merck), BioAssets development Corp (sold to Cephalon),
Syntonix (sold to Biogen Idec), Health Honors (sold to Healthway) and JB Therapeutics (now public as Corbus Pharmaceutical Holdings).
Prior to founding Arnold Strategies, Mr. Arnold spent 20 years as the CEO of multiple private and public
technology and life science companies. Among these include Cambridge Heart, a cardiology diagnostics
company which he founded and took public, CardioFocus, a VC backed catheter ablation company and Accelrys, a public company with software tools for rational drug design, now a division of Dassault Systemes.
Mr. Arnold is a guest lecturer at the MIT Sloan School, mentor at the MIT Venture Mentoring Society, on
the Grant Review Board of the MIT Deshpande Center and on the Board of Overseers at the Museum of
Science. He was formerly Chairman of the Greater Boston Chapter of the American Heart Association. He
received a BSEE from MIT in 1972.
Biographies 7
8th Annual
Denise Aronson
President & Founder, Safety Partners, Inc.
Denise Aronson is a pioneer in the life science health and safety industry. Denise founded Safety Partners
Inc. in 1992. Since then, Denise and her team have implemented safety programs for more than 275 top
life science companies. Prior to founding Safety Partners, Denise served as an environmental, health, and
safety manager at T Cell Sciences, and managed a clinical prenatal diagnostics laboratory. She began her
career as a research associate at Beth Israel Deaconess Hospital in Boston, after receiving a BS in Biochemistry from the University of New Hampshire. Denise is a certified chemical hygiene officer through the
National Registry of Certified Chemists.
She is active in more than 20 professional societies and trade organizations, and was a founding member
of the New Hampshire Bio/Medical Council, Preferred Provider Leads Group; the Tom Vance, Life Sciences
Connector Group; and the Cambridge Chamber of Commerce, Life Sciences Leads Group. She is a regular
on the industry speaking circuit, a member of the MassBio SEF Working Group, and an American Chemical
Society (ACS) Expert. Denise also serves on the Advisory Board for the UMass Lowell Department of Work
Environment as well as the Boards of The Bioscience Network and The Waldorf High School of Massachusetts Bay.
Safety Partners is a Certified Woman-Owned Business, and has been named one of the 25 Best Small Companies by Working Mother magazine.
Abigail Barrow
Founding Director, Massachusetts Technology Transfer Center and Conference Co-Chair
Dr. Abigail Barrow is the Interim Executive Director, Office of Technology Commercialization and Ventures
(OTCV) at the University of Massachusetts. She joined the UMass President’s Office in 2004 as the Founding Director of the Massachusetts Technology Transfer Center (MTTC) which is housed in OTCV. At OTCV
she supports the campus technology transfer programs as well as assisting with start-up formation and other
systemwide entrepreneurship activities at UMass. She is also responsible for the overall management of the
MTTC and the development of its programs. Prior to joining UMass, Dr. Barrow served as managing director
of William J. von Liebig Center at the University of California San Diego (UCSD). The von Liebig Center was
created in 2001 to support the commercialization of research being performed in the UCSD Jacobs School
of Engineering.
Dr. Barrow worked in a variety of roles at UCSD CONNECT from 1990 to 2001. At CONNECT, she developed
and expanded many of its programs to support early-stage company formation and technology commercialization. The CONNECT program is internationally recognized and has been successfully replicated in many
other regions around the world.
Dr. Barrow is on the board and is Chair of VentureWell (formerly the National Collegiate Inventors and Innovators Alliance). Dr. Barrow received her Ph.D. from the Science Studies Unit and a B.Sc. in Mechanical
Engineering from the University of Edinburgh.
8 Biographies
June 2, 2015
Jeff Behrens
President & CEO, Siamab Therapeutics, Inc.
Jeff is President and CEO of Siamab, Inc., a biotech company focused on developing therapeutic antibodies targeting glycan targets in cancer. Previously, Jeff served as Senior Director, Business Development and Operations at Edimer Pharmaceuticals and also worked at Alnylam and Biogen Idec.
In 2003 Jeff sold his healthcare IT company, The Telluride Group, to mindSHIFT Technologies, a Fidelityfunded rollup. Telluride was an information technology managed services provider (MSP) founded in 1995.
Jeff has a Lecturer appointment and currently teaches in the HST PhD program at MIT and Harvard Medical
School. Jeff has an MS from the Harvard/MIT Division of Health Sciences and Technology (HST), an MBA
from MIT Sloan, and graduated from Harvard College. He lives in Newton, MA.
Richard Berenson
CEO, Thermalin Diabetes LLC
Rick is a serial entrepreneur who has successfully launched and financed multiple life science and other
organizations around important new technologies in complex markets. He has been CEO or COO of eleven
companies; most recently Thermalin Diabetes, LLC (CEO, biotech) and HeartLander Surgical, Inc. (CEO,
medical device). Rick has also led companies in consumer products manufacturing, knowledge management, new media, entertainment industry technology, manufacturing software, healthcare information and
services, healthcare market research, diagnostic reference laboratory services, and cancer immunotherapeutics. He has raised or helped raise more than $50M in private and non-dilutive capital. A former McKinsey
& Company consultant, Rick received a JD-MBA from Harvard Business and Law Schools in 1984 and is a
graduate of Harvard College.
Rick began his career at AT&T Bell Laboratories as a member of technical staff where he helped launch internal ventures. He then worked at several software startups in the Boston area before joining McKinsey & Company as a management consultant. Subsequently, Rick has been CEO of ActivBiotics (early stage biotech),
Banton Precision Wood Products (consumer products manufacturer), NewSphere (knowledge management
software), Student.Com, Inc. (new media), and TVGrid (technology for the entertainment industry). He has
also served as COO at ChannelHealth.Com (healthcare information and e-commerce), Morpace Pharma
Group (medical market research), and AltiComm (telecom). Rick has advised other companies through
Paris-based ALLIANCES Management Consultants, Monadnock Associates, and most recently Venzyme
Catalyst, LLC where he is Managing Director. He serves on the boards of SimulConsult (medical diagnosis
decision support software), InCytu (cancer immunotherapy), Massachusetts Medical Angels (angel investing
group), and The Freedom Trail Foundation.
Biographies 9
8th Annual
Edward Berger
Principal & Founder, Larchmont Strategic Advisors
Edward Berger has nearly 30 years experience in health services, medical technology and life sciences reimbursement, strategic planning, regulatory policy and corporate communications. Through his consultancy,
Larchmont Strategic Advisors, he helps life sciences companies create and implement integrated strategies
to address the obstacles and opportunities they face in their efforts to secure public and private insurer coverage and optimal reimbursement for new or evolving technologies. Focusing on issues that arise at the
intersection of public policy, corporate strategy development, and internal and external advocacy, Dr. Berger
helps clients to deal effectively with the strategic challenges posed by the rapidly evolving healthcare regulatory and policy environment. His clients have included companies in fields such as mechanical circulatory
support, cardiology, orthopedics, neural monitoring and neuromodulation, gastrointestinal surgery, pulmonary medicine, nuclear medicine, diagnostic imaging, clinical laboratory testing, and personalized medicine.
Previously, as a member of the senior management teams of Fresenius Medical Care, Thermo Cardiosystems and ABIOMED, Dr. Berger had primary responsibility for the development and
implementation of reimbursement strategy and advocacy as well as the broader range of strategically sensitive communications with government agencies, news media and investors.
Dr. Berger also serves as President of cardiothoracic device developer Coraux Technologies, LLC and as a
Director of Atanse, Inc., an early stage neurosurgical instrument company. He is a member of Mass Medical
Angels, a mentor in Boston University’s IGNITE program, and Past President of the Medical Development
Group, a 400 member professional association of individuals professionally committed to the medical device
and related life sciences business sectors.
He has a Bachelor’s Degree in Government from Harvard College, and earned his Ph.D. in Political Science
at Boston University, where he was later Assistant Professor of Political Science and Chair of the Urban Affairs and Planning program.
Carl Berke
Partner, Partners HealthCare Innovation Fund
Carl is a Partner at Partners HealthCare Innovation Fund in Boston, investing in new biomedical technologies
emerging from Massachusetts General Hospital and Brigham & Womens Hospital. His career has spanned
over 25 years in the practice and management of innovation to bring new technologies from lab to market.
As a bench scientist and R&D director, he worked at Polaroid Corporation and Hygeia Sciences in the development of photographic and clinical products – he is an inventor on 6 US patents. He served as a Partner
at Integral/Analysis Group, a management consultancy focused on innovation and growth strategy. He has
been an active private equity investor as a member of Angel Healthcare Investors LLC and is a founding
director of Mass Medical Angels LLC. He has served on the boards of Quosa [literature management software], Kasalis [robotics], Annovation [novel anesthetics], Combinent [drug delivery], Sebacia [acne treatment], Infobionic [cardiac monitoring], QPID Health [bioinformatics], LifeImage [diagnostic image sharing],
Syntimmune [autoimmune therapy] and the Sudanese Education Fund [philanthropy].
Carl holds an AB degree from Cornell University and received his PhD in Organic Chemistry from the University of California at Berkeley. He also holds an appointment as Lecturer in the Biomedical Enterprise Program
in the Harvard-MIT Division of Health Sciences and Technology.
10 Biographies
June 2, 2015
Pravin Chaturvedi
Founder & Chairman, IndUS Pharmace
Dr. Chaturvedi is the Founder and Chairman of Boston-based IndUS Pharmaceuticals and a co-founder of
Florida-based Oceanyx Pharmaceuticals and also serves as the Chief Executive Officer of both these organizations. He also serves as the Chief Scientific Officer of San Francisco-based Napo Pharmaceuticals.
Previously he has served as the President and Chief Executive Officer of Boston-based Scion Pharmaceuticals. Dr. Chaturvedi serves on the boards of IndUS, Oceanyx, FuelEd Schools, Cellanyx, PRADAN USA and
Sindu Research Laboratories. He has previously served on the Boards of Scion Pharmaceuticals and TiE
Boston. He also serves as an advisory board member to TFC Biosciences and Springboard Enterprises and
is the Chair of the Research Advisory Council for the Health Sciences Center of West Virginia University. He
is an adjunct faculty member at Georgetown Medical School.
Over his 25+ year career, Dr. Chaturvedi has participated or led the discovery and/or development activities
for several new chemical entities (NCEs), culminating in the successful development and commercialization of several new drugs that are currently marketed by various companies. Prior to his roles at IndUS,
Oceanyx, Napo and Scion Pharmaceuticals, Dr. Chaturvedi, spent several years at Vertex Pharmaceuticals
as the Head of Lead Evaluation. Prior to Vertex, he was in the preclinical group at Alkermes and he started
his R&D career in the Product Development group at Parke-Davis/Warner-Lambert Company (now Pfizer).
Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor’s in
Pharmacy from the University of Bombay.
Will Cowen
Managing Partner, Long River Ventures
Will has extensive experience building early stage companies both as an entrepreneur and as venture
investor. Prior to joining Long River Ventures he was a co-founder and CEO of NaviNet with backing
from Northbridge, Atlas, and GE Equities. Today NaviNet is a leading healthcare IT firm which streamlines transactions between healthcare payers and over 800,000 healthcare providers. Prior to NaviNet,
Will was CEO of venture-backed Pegasus Medical Technologies, an electronic medical records company
sold to HBOC/ McKesson (NYSE:MCK). Early in his career Will was a co-founder of a consumer products company, Thermocell, which is today a $500 million dollar division of the Hunter Douglas Company.
On the investing side, Will was a Managing Partner of Interface Technologies and Firepond Partners, two
early stage healthcare funds. Will serves, or has served, on the board of numerous companies including
Convergent Dental, GetWellNetwork, LifeIMAGE, Medical Metrix Systems, MedVentive, Parsagen Diagnostics, Phreesia, Solais, and Verax Biomedical.
Will holds a B.A. from the University of Colorado and a M.B.A. from the Massachusetts Institute of Technology.
Biographies 11
8th Annual
Prem Das
Chief Research Business Development Officer, The Belfer Office for Dana-Farber
Innovations (BODFI)
Prem joined BODFI in 2012. His background includes managing academic technology transfer offices, biotechnology business development, and basic research. Most recently, Prem was involved in creating start-up
companies and consulting to biotechnology companies and the NCI. Prior to joining BODFI, he served as
Senior Vice President for Technology Alliances at Praecis Pharmaceuticals, where his business development
efforts led to the acquisition of the company by Glaxo-Smith Kline in 2007.
Before Praecis, from 2003 to 2006, Prem directed the Office of Technology Licensing at Harvard Medical
School. From 2000 to 2003 he was Associate Director of the Office of Industrial Affairs at Memorial SloanKettering Cancer Center. Earlier, he worked at Mount Sinai School of Medicine and Cadus Pharmaceuticals,
and co-founded Heartland BioTechnologies. During his academic research career, Prem has published in
diverse areas of biology.
He received his MSc in Chemistry from IIT/Kanpur in India and his PhD in Biological Chemistry from MIT.
Bill Edelman
Chairman of the Board, Vitathreads LLC
Bill Edelman, is a medical device industry executive with over 35 years experience and currently serves
as Chairman of the Board for Vitathreads LLC, (aesthetics wound repair) NewVert, Ltd., (spinal implants),
Highland Instruments, Inc., (neurostimulation), Paragonix Technologies, Inc., (organ transport systems), Medivalve, Ltd., (percutaneous aortic valve placement), and Cardioflow, Ltd., (embolic protection). CEO for
ETView, Ltd., (TASE: ETVW) (airway management). Mr. Edelman also serves as a Board Member for MindChild Medical, Inc., (non-invasive fetal monitoring). Mr Edelman is an Advisor on the Heathcare Board, for
Northeast Securities, Inc., Advisor to First Light Bioscienses, Inc. (automated medical diagnostic products),
and serves as a member of the Advisory Council for the Department of Biomedical Engineering at Rensselaer Polytechnic Institute.
Mr. Edelman previously served as a member of the Screening Committee for Medical Devices for Mass
Medical Angels, Chairman of the Board for Flexicath, Ltd., (IV catheterization), PolyTouch, Ltd., acquired by
Covidien in 2011 (general surgical instrumentation), Stimatix GI, Ltd., (ostomy products) and Leviticus Cardio, Ltd., (cardiac assist power systems).
Previously, Mr Edelman served as President & Chief Executive Officer, TYRX, Inc., a commercial
stage venture backed medical device company focused in drug/device implant products for general surgery, electrophysiology and cosmetic surgery. TYRX was acquired by Medtronic, Inc., in 2014.
Prior to TYRX, Mr. Edelman held executive level positions at MicroSense International, LLC (bio-sensing),
FibraSonics, Inc. (ultrasonic surgical products), NeuroMod, Inc. (neuro-stimulation technologies), St. Jude
Medical, Inc., Pfizer, Inc., and Baxter International, Inc.
Mr. Edelman graduated with a degree in Biomedical Engineering from Rensselaer Polytechnic Institute. He
has been issued 15 U.S. patents and is an applicant on 5 additional pending patent applications.
12 Biographies
June 2, 2015
Tomas Engellenner
Partner, Pepper Hamilton LLP
Tom Engellenner is a partner in the Intellectual Property Department of Pepper Hamilton LLP, resident in the
Boston office. Mr. Engellenner’s practice includes strategic IP advice, preparation of opinions, patent prosecution and litigation. He has particular expertise in the fields of biotechnology, medical devices, diagnostics,
drug development and analytical instruments. Mr. Engellenner has more than thirty years of experience in
prosecuting and litigating patents and advising clients generally on intellectual property strategies.
Thomas Forest Farb
President, Thrive Bioscience, Inc.
Thomas Forest Farb has three decades of experience as an entrepreneur, investor, senior executive and
mentor in early-stage information technology and life science companies in Massachusetts, California, Florida, Puerto Rico and China. As an entrepreneur, Mr. Farb has been directly involved in founding and in raising
more than $135 million of angel and venture capital for over ten companies.As an investor, he has been a
partner in two venture capital/private equity firms in Boston and China and as Executive Director of the Trust
for Science & Technology in San Juan, Puerto Rico. As a senior executive, he has served as President, COO
or CFO of numerous companies, including Atherio Information Systems, Indevus Pharmaceuticals, MedicaMetrix and Cytyc.As a mentor, he has been a Mentor for the Founder Institute and a Senior Advisor at the
Microsoft Innovation Center, both in San Juan, Puerto Rico.
Mr. Farb is currently President of an early stage life sciences company in the Boston area, Thrive Bioscience,
Inc., which is building instruments to automate laboratory and therapeutic cell culture and has just raised
more than $3.5 million in seed financing. Mr. Farb has been a member of the Board of Directors of numerous
companies including several public companies -- Fair Isaac (NYSE: FIC), Redwood Trust (NYSE: RT), HNC
Software (NASD: HNCS), Retek Systems (NASD: RETK), and Symon Communications (NASD: MGN).
He has been a Trustee or Advisor for numerous non-profit organizations including the Dana Farber Cancer
Institute, Asia America Chamber of Commerce, Partners Healthcare, three private schools and two museums. He is also a Founder and Officer of Brahman Industries, a mission driven company developing floating
shelters for use in natural disaster.
Mr. Farb is a graduate of Harvard University.
Biographies 13
8th Annual
Jonathan Fleming
President, NEHI
Jonathan J. Fleming is President of NEHI, a national health care policy think tank. Founded in 2002, NEHI
is a nonprofit, non-partisan, evidence-based institute dedicated to identifying innovations that provide solutions to the most pressing issues facing our health care system today. Since 1999, Mr. Fleming has been
the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life
science investments based in Boston, Massachusetts. Mr. Fleming has been in the investment business for
more than 29 years, starting and financing growth companies in the United States, Europe, Israel and Asia.
Prior to joining Oxford Bioscience Partners in 1996, he was a Founding General Partner of MVP Ventures in
Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany.
Mr. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early
stage health care and biotechnology companies in Israel, and the Korea Seoul Life Science Fund, based in
Seoul, Korea. Mr. Fleming is a director of Xencor (NASDAQ: XNCR) and several private early stage life
science companies. He is also a director of Leerink Partners, a Boston based investment bank specializing
in health care companies. In addition, Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of
Management since 2003, where he co-teaches a class on business strategy for life science managers. He
is an advisor to the SBIR program of the National Cancer Institute.
Mr. Fleming holds a Master’s degree in Public Administration from Princeton University’s Woodrow Wilson
School of Public and International Affairs.
Roger Frechette
Co-Founder & Principal, New England PharmAssociates
Dr. Roger Frechette is the Co-Founder and Principal of New England PharmAssociates, a consultancy offering on-demand executive and business advisory services to life sciences enterprises. He is also the US
East Coast Ambassador for Medicon Valley Alliance, a life sciences cluster organization based in Copenhagen. Previously, he was a Co-Founder of Frontiera Therapeutics, a startup developing therapeutics for
vascular leak. He is a volunteer adviser and mentor with several Boston area biotech incubators and startup
mentoring programs. Previously, Dr. Frechette was Co-Founder of MaxThera, an antibacterial drug discovery company. MaxThera was sold in 2010 to Biota Holdings Limited, a Melbourne Australia anti-infectives
company. Prior to starting MaxThera, Dr. Frechette was a drug discovery and life-sciences consultant following his role as Project Director at Paratek Pharmaceuticals (Boston). At Paratek he led the team that
discovered PTK0796 (currently in Phase III clinical trials) with strategic partner Glaxo-Wellcome, and also
led the pre-clinical development program that was carried out with a multinational team of consultants and
contractors. Previously, he was Associate Director of Chemistry at RiboGene (Hayward, CA), where he built
the chemistry department and managed two drug discovery programs in collaboration with strategic partner
Dainippon Pharmaceuticals. He began his career as a medicinal chemist at the R.W. Johnson Pharmaceutical Research Institute (J&J, Raritan, NJ).
Dr. Frechette was a Post-Doctoral Fellow at Yale University, earned his PhD in Organic Chemistry from Wesleyan University and his BA in Chemistry from College of the Holy Cross.
14 Biographies
June 2, 2015
Michael Greeley
General Partner, Flare Capital Partners
Michael currently serves as a General Partner at Flare Capital Partners. Prior to joining Flare, Michael served
as founding general partner of Flybridge Capital Partners where he led the firm’s healthcare investments. He
also served on the board of International Data Group, the initial flagship Limited Partner for the IDG Ventures
global network of funds and Flybridge Capital Partners.
Current and prior board seats include BlueTarp Financial, Explorys, Functional Neuromodulation, Iora Health,
MicroCHIPS, Nuvesse, PolyRemedy, Predictive Biosciences, Predilytics, T2 Biosystems, TARIS Biomedical
and VidSys.
Previously, Michael focused on emerging-growth company financings with Polaris Venture Partners, was a
senior vice president and founding partner of GCC Investments, and held positions at Wasserstein Perella &
Co., Morgan Stanley & Co. and Credit Suisse First Boston.
Michael currently serves as chairman of the Entrepreneurship Committee of the Massachusetts Information
Collaborative and on the Investment Committee for the Partners Innovation Fund and Massachusetts Eye &
Ear Infirmary. Michael also serves on the Industry Advisory Board of the Cleveland Clinic, as well as serving
on several other boards including the New England Investors’ Committee of Capital Innovation. He was the
former chairman of the New England Venture Capital Association and on the Executive Committee of the
board of the National Venture Capital Association. Named by the Boston Globe as the “Go-To” investor for life
sciences, healthcare and medical devices and a Mass High Tech All-Star, Michael earned a B.A. with honors
in chemistry from Williams College and an M.B.A. from Harvard Business School.
Geraldine Hamilton
President & CSO, Emulate
Dr. Hamilton’s career spans academic research, large Pharma, and biotech start-ups, with over 10 years’
experience in the pharmaceutical industry. In all three arenas, Dr. Hamilton’s work has focused on the development of new human-relevant cell-based models and their application to drug discovery. This pursuit
brought Dr. Hamilton to Harvard’s Wyss Institute, where as a Lead Senior Staff Scientist she directed the
extensive Organs-on-Chips project. This project was successfully spun-out from the Wyss Institute to form
Emulate, Inc., where Dr. Hamilton now serves as President and Chief Scientific Officer. At Emulate, Dr.
Hamilton continues her work to further develop Organs-on-Chips technology as well as to drive and facilitate
its adoption in commercial use. Prior to joining the Wyss Institute and Emulate, Dr. Hamilton was one of the
founding scientists of the biotech start-up CellzDirect, where she was the VP of Scientific Operations and
Director of Cell Products. CellzDirect successfully translated and commercialized technology from academic
research to supply the pharmaceutical industry with hepatic cell products and services for safety assessment
and drug-metabolism studies.
Hamilton received her Ph.D. in cell biology/toxicology from the University of Hertfordshire (England) in conjunction with GlaxoSmithKline, followed by a post-doctoral research fellowship at the University of North
Carolina. She has led in vitro toxicology and drug metabolism teams in GlaxoSmithKline and AstraZeneca.
Her current research interests and scientific experience include: bioinspired engineering, toxicology and
drug metabolism, liver cell biology, mechanisms regulating gene expression and differentiation, regulation
of nuclear receptors and transcriptional activation in hepatocytes by xenobiotics, human cell isolation and
cryopreservation techniques.
Biographies 15
8th Annual
Paulina Hill
Principal, Polaris Partners
Paulina Hill is a Principal at Polaris Partners. Paulina joined Polaris in 2011 and focuses on investments in
healthcare.
Paulina serves on the boards of Arsenal Medical, Faraday Pharmaceuticals and KinDex Pharmaceuticals
and is an observer on the boards of MicroCHIPS and 480 Biomedical. Paulina also works closely with Arsia
Therapeutics, an early-stage Bob Langer-founded startup which she was actively involved in spinning out of
MIT. Paulina serves on the board of The Capital Network, a non-profit that provides fundraising education
to startup entrepreneurs and is part of the Lead Mentor team for Canadian Entrepreneurs in New England.
Prior to joining Polaris, Paulina completed her postdoctoral fellowship in the Chemical Engineering department at the Massachusetts Institute of Technology. In the laboratory of Bob Langer, Paulina worked on developing novel biomaterial scaffolds and drug delivery systems for neural applications. Paulina is the founding president of the MIT Postdoctoral Association, and served on the MIT Intellectual Property Presidential
Committee.
Paulina completed her PhD in Molecular Medicine with a Tissue Engineering focus at Wake Forest University School of Medicine. Her graduate school work resulted in over 40 published abstracts, awards and peer
reviewed manuscripts. Her research contributed to numerous patents and the formation of the startup KeraNetics to commercialize the platform technology. Paulina graduated magna cum laude from East Carolina
University with a quadruple major in biochemistry, neuroscience, biology and chemistry. She attended East
Carolina on an athletic scholarship where she was captain of the women’s tennis team.
Laura Housman
Senior Vice President, Molecular Health
Ms. Housman joined Molecular Health in October 2013 as Senior Vice President, Chief Commercial Officer.
In that role, Ms. Housman was responsible for the commercialization of Molecular Health’s suite of treatment
decision support tools for enhanced oncology clinical care, successfully launching its first product, TreatmentMAP. Beginning April 2015, Ms. Housman now has responsibility for developing the strategic plan and
commercializing intellectual property associated with a novel erythropoietin receptor discovered by Molecular Health’s computational software platform, Nucleus, as Senior Vice President, Corporate Development.
By using advanced proprietary information technologies to sift through terabytes of genetic and molecular
test findings in a fraction of the time needed for current manual analysis, MolecularHealth provides doctors
and patients with faster, more accurate insights into the role genes play in the progression and treatment of
an individual’s cancer.
Ms. Housman holds a Master of Business Administration with honors from Boston University Graduate
School of Management, a Master of Public Health with specialization in Health Services from Boston University School of Public Health, and a Bachelor of Arts degree in Economics with a minor in Business Administration from Boston University College of Arts and Sciences. Additionally, Ms. Housman is on the Faculty of
Tufts School of Medicine in Boston, Massachusetts. Ms. Housman is based in the Cambridge Massachusetts
U.S. business office for Molecular Health, with global headquarters in Heidelberg, Germany and a CLIA/CAP
laboratory in The Woodlands, Texas.
16 Biographies
June 2, 2015
Mason (Skip) Irving, III
Vice President, Stemnion, Inc
For over 30 years Skip has been advising companies on business strategy, product commercialization, R&D
planning and business development in the biotech, pharmaceutical and medical products industries.
Skip now serves as Vice President for Stemnion, Inc., a Pittsburgh-based biotechnology company developing novel biologic products for tissue healing.
Until recently Skip was a Managing Director at Health Advances. Joining in 1997, Skip helped create a
leading life-science focused management consulting firm with over 100 professional staff. Skip’s practice
included Fortune 500 companies, venture-backed start-up companies and not-for-profit disease foundations
and leading academic centers.
Prior to joining Health Advances, as Vice President for Commercial Development at the Massachusetts Biotechnology Research Institute (MBRI), Skip was involved in the founding of seven life sciences companies
and created a unique technology licensing office representing eight academic research institutions and over
$200 million in research. He helped found and served on the Board of t-Breeders, a cellular therapy company eventually purchased by Perkin Elmer.
Prior to MBRI, Skip was Vice President and Director of Worldwide Healthcare Consulting at Arthur D. Little,
Inc. where his professional work involved technology planning, R&D management, and strategic alliances.
Skip also worked in manufacturing and quality assurance for the sterile parenteral business at AstraZeneca .
Skip is a frequent speaker at industry conferences including the Biotechnology Industry Organization and
the Licensing Executives Society. He serves on the Board of the Michael J. Fox Foundation for Parkinson’s
Research and the Industry Advisory Committee for the Brain Tumor Society. He is also a member of the College Corporation at the Massachusetts College of Pharmacy and Health Sciences where he earned his BS
in Pharmacy and serves on the Board of Overseers for Mount Auburn Hospital. Skip earned his MBA at the
Amos Tuck School at Dartmouth College.
Curtis Keith
CSO, Blavatnik Biomedical Accelerator at Harvard University
Dr. Keith is Chief Scientific Officer of the Blavatnik Biomedical Accelerator at Harvard University, an innovative program bridging the gap between early-stage life science research at Harvard and successful development of high-impact biomedical products. Prior to joining Harvard University in 2008, Dr. Keith was Senior
Vice President of Research at CombinatoRx, a Massachusetts-based biotechnology company which he
cofounded in 2000. Under his leadership, CombinatoRx created an integrated technology platform for the
discovery of multi-target therapeutics, yielding a broad pipeline of preclinical and clinical drug candidates in
areas including rheumatoid arthritis, psoriasis and neurodegenerative disease.
Dr. Keith earned his B.Sc. in biochemistry from McGill University and received his Ph.D. in chemistry and
chemical biology from Harvard University.
Biographies 17
8th Annual
Roger Kitterman
Executive Director, Boston Biomedical Innovation Center
Roger is an experienced venture capital investor with more than 20 years in the industry and has guided
multiple venture-backed companies through the earliest stages of development. He has also been the
startup CEO for three venture-backed companies and is a founder of Mass Medical Angels. Previously, he
was a general partner at Mi3 Venture Partners, an early stage, bioengineering focused fund. Prior to joining
Mi3, he was a managing director at Lee Munder Venture Partners, the venture capital arm of Lee Munder
Capital Group. He joined Lee Munder from Boston University’s Community Technology Fund, where he
made venture capital investments in the life sciences and developed and managed spinouts from the
university and Boston Medical Center. Roger began his venture capital career in Eastern Europe with the
Bulgarian- American Enterprise Fund, a $55 million venture capital fund.
Roger holds an MBA in Finance and Business Development from the Columbia Business School and an
AB from Harvard College. He is also the Executive Director of the Boston Biomedical Innovation Center
(www.b-bic.org). Representative Fund investments include CoStim Pharmaceuticals, Daktari Diagnostics,
Provasculon, TargAnox, and VisionScope.
Imran Nasrullah
Director, Innovation Sourcing, Boehringer-Ingelheim Pharmaceuticals
As a member of Boehringer’s Therapeutic Alliances and Strategic Partnerships team, Imran is responsible
for forging business relationships within the Boston/Cambridge life-science ecosystem to facilitate access
to new scientific innovation emerging from the Boston area.
Previously, Imran served as Senior Advisory Board member at Cellanyx and as Head of Strategic Alliances
at T1D Exchange. As Head of Strategic Alliances, Imran’s responsibilities included forging new business
relationships with industry, academic and not-for-profit partners, as well as maintaining partnerships with
existing partners in these same sectors.
Mark Ralph
Director, External Partnership Operations, Boehringer Ingelheim Pharmaceutecals
Mark Ralph is a member of the Research Networking and Strategic Planning department in Boehringer
Ingelheim’s Ridgefield research organization. In his current function, he is responsible for identifying new
discovery stage collaboration opportunities with academic and biotech partners. As leader of the External
Partnerships and Contract Operations (EPCO) group, Mark also represents Research interests in the negotiation and execution of agreements with universities and technology companies.
Mark joined Boehringer Ingelheim in 2001 as a medicinal chemist. Since this time, he has transitioned
into several diverse roles with increasing responsibility. As a manager for external chemistry resources,
he helped drive global productivity increases from contract research organizations around the world. This
was followed by a stint in finance where he provided fiscal guidance to brand teams in the prescription
medicine organization.
Mark holds a MS degree in chemistry from Memorial University (Canada) and a MBA with concentration
in finance from the University of Connecticut. He is included as an inventor on five patents and an author
on three scientific publications.
18 Biographies
June 2, 2015
Ruben Salinas III
Co-founder, President & CEO
Mr. Salinas is the cofounder, President & CEO of Parsagen Diagnostics, a company focused developing and
commercializing breakthrough invitro diagnostics in the women’s health arena. Most recently, he served as
Executive Vice President of AmniSure International, a company that disrupted the landscape of obstetrical
diagnostics through the introduction of proprietary rapid assays based on the PAMG-1 protein marker. The
company was acquired by Qiagen N.V. in May, 2012. Prior to AmniSure, he was President & CEO of MPI, a
world-leader in diagnostic-imaging surfaces. Previously, he was Director of Strategic Marketing at C.R. Bard
and held diverse Product Management, Six Sigma and Operations positions at GE Healthcare and other GE
divisions. He holds an MBA from the Harvard Business School and a BS Industrial Engineering from the Instituto Technologico y de Estudios Superiores de Monterrey, and is a nationally-certified Emergency Medical
Technician.
Scott Samuels
Partner, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Scott’s practice focuses on corporate and securities law matters, primarily for life sciences and technology
companies. Scott has represented both private and public companies, venture capital funds, angel investors
and other parties in a broad range of transactions, including the formation and growth of start-up and emerging companies, private and public offerings, and mergers and acquisitions. For start-up and earlier stage
companies, Scott advises on formation, financing, equity compensation, contracts and employee/consultant
agreements, and also coordinates with the firm’s specialists in IP, employment, immigration and other areas
as needed.
Aaron Sandoski
Co-founder & Managing Director, Norwich Ventures
Aaron Sandoski is Co-founder & Managing Director of Norwich Ventures, a specialized venture capital firm
focused on early-stage MedTech. Aaron sits on the boards of Daktari Diagnostics, Pelvalon, Podimetrics,
Soffio Medical, and Vaxess Technologies. Previous investments include Rhythmia Medical (acquired by
Boston Scientific) and Intelligent Bio-systems (acquired by Qiagen). Prior to founding Norwich Ventures,
Aaron worked for DEKA R&D, the engineering think tank of Dean Kamen. He has also worked in start-up
operations where he helped launch a subsidiary of Express Scripts and helped launch a venture-backed payments company. Aaron began his career as a consultant at McKinsey & Company, where he advised healthcare clients ranging from leading medical device companies to a rural hospital system. Aaron is co-author of
How the Wise Decide (Crown Business), a book on best practices in making tough decisions.
Aaron earned an MBA from Harvard Business School and graduated summa cum laude from Dartmouth
College with a double A.B. in Chemistry and Economics.
Biographies 19
8th Annual
Kevin Scanlon
Founder & CEO, International BioScience
Dr. Kevin Scanlon’s career spans roles in academic medicine, senior management in the pharmaceutical
industry and biotech companies, as well as an individual investor. Dr. Scanlon was identified by LA Techweek
in 2013 as an individual impacting the Los Angeles business and the technology landscape on a significant
scale.
During the two years Dr. Scanlon served as the Chairman of Pasadena Angels Investment Group, ~100 investors funded over 50 companies for $9.0 MM. He has been CEO of four biotechnology companies, including Melanoma Diagnostics, which was sold to Myriad Genetics. At Berlex-Schering AG (Berlin, Germany), he
was responsible for the genomic and cancer programs in the US, Europe and Asia.
Dr. Scanlon’s notable academic achievements include: Leukemia Society Scholar, Paul Martini Medical Research Prize (Cancer, Germany), Co-Founder and Editor of the Nature Journal “Cancer Gene Therapy”,
President of the International Society of Cell and Gene Therapy, co-authoring 135 peer-reviewed scientific
articles and nine medical books. Dr. Scanlon also holds seven issued US Patents.
Katie Stebbins
Assistant Secretary of Innovation, Technology, and Entrepreneurship, Massachusetts’
Executive Office of Housing and Economic Development
Katie has twenty years of experience in city and regional, and workforce and economic development. She
served the City of Springfield for ten years, specializing in environment planning and brownfield redevelopment, worked for the Cecil Group in Boston, and served as the Western Massachusetts Director for Mass.
Mentoring Partnership. Most recently, Katie ran her own consulting practice and was the primary consultant
for the Holyoke Innovation District on behalf of the Massachusetts Tech Collaborative. She is also an entrepreneur, who actively participates in the mentoring and accelerator space, and launched her own civic tech
startup in 2012. She is a resident of Western Massachusetts.
John Tagliamonte
Chief Business Officer, Oxyrane
Mr. Tagliamonte has over 15 years of experience in executive leadership positions with responsibility for
finance, business development, commercial and business operations, strategic planning and legal functions
with established and emerging public and private life sciences companies. He is Chief Business Officer of
Oxyrane a biopharmaceutical company developing treatments for rare diseases and on the Advisory Board
of Cocoon Biotech. He previously served on the advisory board of BioHelix Corp. Previously he was VP
Business Development at Anchor Therapeutics and ImmunoGen and Director worldwide BD&L at Johnson
& Johnson. He began his career as a research scientist at Dana-Farber Cancer Institute followed by global
commercial roles at Bio-Rad.
Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.
20 Biographies
June 2, 2015
Seth Taylor
CFO & CBO, Mass Innovation Labs
Seth has over 17 years of industry experience that combines corporate business development, corporate
advisory services, and founding life science companies. As Managing General Partner at Vectur LLC and
before that a Principal at TSG Partners, he developed growth strategies and worked on a wide range of strategic mandates for leading life science companies. He was co-founder of Molecularware, Inc., a life science
informatics company, and prior to that an executive in business development at Packard Bioscience. He
received his BS from Cornell University, his PhD from The Johns Hopkins University, and his SM from the
Sloan School of MIT.
Josh Tolkoff
Managing Director, Ironwood Equity Fund
Josh works at CIMIT, Center for Integration of Medical and Innovative Technology, accelerating the commercialization of suitable projects. In addition, he is a Managing Director of Ironwood Equity Fund, a later stage
venture investor in healthcare and specialty manufacturing companies. Prior to Ironwood, Josh founded and
managed Seedling Enterprises, considered one of the most successful medical device accelerators funds.
Josh founded ACT Medical, which became a premier medical device contract developer and manufacturer.
In 10 years he lead ACT’s growth to over $20 million before it was sold to MedSource. Josh started Harbor
Medical Devices, a venture backed medical device company. Prior to founding Harbor, Josh was head of
research and development for over 9 years for Medi-Tech, the founding division of Boston Scientific. He
held this role as the company grew from 20 to over 500 employees.
He currently is a corporate Director of numerous for-profit growth companies. He is a board member and past
chair of MassMedic and the advisory board of the Harvard-MIT program in Health Sciences and Technology.
He is the founding board chair of Interise, a non-profit helping small urban companies develop and execute
a new growth plan. Interise has grown from 1 to over 20 cities through a partnership with the SBA.
Josh received a Bachelor degree with concentration in Engineering and Applied Physics from Harvard College in 1970 and a Masters degree in Mechanical Engineering with a major in BioMechanics from MIT in
1971.
Roger Tung
Co-Founder, President & CEO, Concert Pharmaceuticals
Dr. Tung is the scientific founder, President, and CEO of Concert Pharmaceuticals (NASDAQ: CNCE). Previously, Roger was a founding scientist at Vertex Pharmaceuticals, where he worked from 1989 to 2005, most
recently as Vice President of Drug Discovery. Prior to Vertex, Roger held various positions at Merck, Sharp &
Dohme Research Laboratories and The Squibb Institute for Medicinal Chemistry. At Vertex, he co-invented
the FDA-approved HIV protease inhibitors Lexiva® and Agenerase® and oversaw the discovery of Incivek®
and Kalydeco®, which were approved, respectively, to treat hepatitis C infection and cystic fibrosis caused
by gating mutations of the CFTR. Roger has published and presented widely in the US and abroad and is an
inventor on over 75 issued U.S. patents. He received his B.A. in chemistry from Reed College and his Ph.D.
in Medicinal Chemistry from the University of Wisconsin-Madison, where he serves on the Board of Visitors.
Roger has been a Scientific Advisory Board member to both public and private biotechnology companies and
has a long-standing interest in company formation and entrepreneurialism.
Biographies 21
8th Annual
Eric Walters
CEO, Co-Founder & Director, ONEighty C Technologies Corporation
Eric G. Walters is CEO, a Co-Founder and Director of ONEighty C Technologies Corporation. The Company
owns WAVEPulseTM Technology, an advanced medical sterilization platform. He has been involved in private and public company fund raising for more than 20 years. Mr. Walters has raised more than $100M in
capital.
Mr. Walters was formerly EVP/CFO and a member of the original senior management team that grew a $1M
medical device start-up company (PolyMedica) to $350M in profitable revenues, later sold for $1.5B in cash
when its revenues exceeded $675M. Mr. Walters is a CPA and has managed investor relations for a publiclyheld corporation with a $1B market capitalization. He was formerly a Big Four auditor and serves on several
Boards of Directors. Mr. Walters has been a C-level executive of both life science and clean technology
companies.
Darshana Zaveri
Partner, Catalyst Health Ventures
Darshana Zaveri is a Partner and a member of Catalyst’s investment committee. Darshana is actively involved in all aspects of Fund Management including Investments and Capital Raising. She led Catalyst’s
investments in Augmenix, Lantos Technologies, nVision Medical, Maxwell Health, Aria CV and Hepregen.
She currently represents Catalyst on the Boards of Lantos (past Chair), nVision, Aria CV, Augmenix and
Maxwell Health and was actively involved with portfolio company Allegro Diagnostics (acquired by Veracyte
Inc.). Prior to Catalyst, she was an Investigator at Vertex Pharmaceuticals and an integral part of the drug
development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome
Therapeutics, a Massachusetts-based biotechnology company, at the Dana Farber Cancer Institute and
completed an internship at the United Nations. She has authored several publications and scientific journal
articles and currently serves as a Catalyst of the Deshpande Center for Technological Innovation at MIT.
Darshana received an MPA from Harvard University, a Master in Cell and Molecular Biology from Boston
University, and a BS in Biochemistry from Bombay University in Bombay, India.
22 Biographies
June 2, 2015
MALSI Day Planning Committee
Chair
Abi Barrow, Massachusetts Technology Transfer Center
Content
Richard Anders, MA Medical Angels
Abi Barrow, Massachusetts Technology Transfer Center
Carl Berke, Partners Healthcare
Roger Frechette, New England PharmAssociates
Lauren Laidlaw, Decision Resources Group
Alan Lucas, CMC Consulting Group
Imran Nasrullah, Boehringer Ingelheim
Marketplace
Shelley Amster, ShelleyCO, LLC
Research & Startup Showcase and Logistics
Tatiana Demidova, Harvard University
Julia Goldberg, Massachusetts Technology Transfer Center
Alex Simon, Harvard Biotech Club
Reception
Denise Aronson, Safety Partners, Inc.
Lauren Laidlaw, Safety Partners, Inc.
Team
Anu Ahuja, Brandeis University
Nina Green, Consultant
Suzanne Grillo, Institute for Pediatric Innovation
Kevin O’Sullivan, MA Biotech Incubator
Avi Spier, Novartis
Maude Tessier, Merck
Planning Committee 23
8th Annual
24 Sponsors & Organizers
June 2, 2015
Sponsors and Organizers
Gold Sponsors....................................................................................................................................... 26
Massachusetts Life Sciences Center........................................................................................................................26
Pepper Hamilton LLP....................................................................................................................................................27
Silver Sponsors...................................................................................................................................... 28
Boehringer Iingelheim Pharmaceuticals................................................................................................................28
MassBio..............................................................................................................................................................................28
Mass Innovation Labs, LLC .........................................................................................................................................29
MintzMintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.................................................................................29
Conference Supporters...................................................................................................................... 30
Lathrop & Gage LLP ......................................................................................................................................................30
MassGlobal Partners......................................................................................................................................................30
Organizers............................................................................................................................................... 31
Massachusetts Technology Transfer Center..........................................................................................................31
Mass Medical Angels ....................................................................................................................................................32
Harvard Biotechnology Club......................................................................................................................................32
MALSI..................................................................................................................................................................................33
In association with .............................................................................................................................. 34
Boston Life Science Networking ..............................................................................................................................34
CIMIT...................................................................................................................................................................................34
Harvard Alumni Entrepreneurs.................................................................................................................................34
Lemelson-MIT..................................................................................................................................................................34
M2D2...................................................................................................................................................................................34
MASS-AWIS ......................................................................................................................................................................34
Massachusetts Biomedical Initiatives .....................................................................................................................34
MassChallenge Inc.........................................................................................................................................................34
MassMedic........................................................................................................................................................................34
Massachusetts Technology Collaborative ............................................................................................................34
Massachusetts Technology Leadership Council..................................................................................................34
NEHEN................................................................................................................................................................................34
North Shore InnoVentures .........................................................................................................................................34
OPEN ..................................................................................................................................................................................34
Safety Partners, Inc. .......................................................................................................................................................34
The Bioscience Network ..............................................................................................................................................34
The Capital Network .....................................................................................................................................................34
TiE.........................................................................................................................................................................................34
VentureWell .....................................................................................................................................................................34
WEST...................................................................................................................................................................................34
University of Massachusetts.......................................................................................................................................34
Sponsors & Organizers 25
8th Annual
Gold Sponsor
June 2, 2015
Gold Sponsor
Biologically
Ever get the feeling that your lawyers don’t understand
what you do? They may know the law, but science
or your business? Not so much. You need a law firm
steeped in life sciences, who will be your ally at every
step from the lab bench to the board room — from
the molecule to the market. A law firm with more than
half a century of experience in helping scientists and
their businesses succeed. You need lawyers who know
you and the science — Pepper Hamilton LLP.
We are proud to support
Massachusetts Life Sciences.
www.pepperlaw.com
Berwyn | Boston | Detroit | Harrisburg | Los Angeles | New York | Orange County
Philadelphia | Pittsburgh | Princeton | Silicon Valley | Washington | Wilmington
8th Annual
Silver Sponsors
June 2, 2015
Silver Sponsors
We are proud to support
The Massachusetts Technology Transfer Center
and the innovators who transform today’s
ideas into tomorrow’s discoveries.
Boston | London | Los Angeles | New York | San Diego | San Francisco | Stamford | Washington | www.mintz.com
8th Annual
Conference Supporters
Lathrop & Gage is proud
to support Massachusetts
Life Sciences Innovation Day
We salute this opportunity for the science and business
communities to connect and collaborate.
CA LIFOR NI A | COLOR A DO | ILLINOIS | K A NSAS
M ASSACHUSETTS | MISSOU R I | N EW YOR K
( 8 57 ) 3 0 0 - 4 0 0 0 | L AT H RO P G AG E .C O M
The choice of a lawyer is an important decision and should not be based solely upon
advertisements. For more information, contact Giulio DeConti at (857) 300-4000.
www.massglobalpartners.com
June 2, 2015
Organizer
The Massachusetts Technology Transfer Center is funded by the Commonwealth of Massachusetts. Its goal
is to support technology transfer activities from public and private research institutions to companies in Massachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research
institutions; faculty, researchers, and students who have commercially promising ideas; and companies across
the Commonwealth.
_______________________________________________________________________________
The Center:
•
facilitates and accelerates technology transfer between research institutions and Massachusetts
companies;
• promotes collaboration between research institutions and the Commonwealth’s technology industry;
• assists in the growth of Massachusetts companies, including startups, by enhancing technological leadership; and
• supports regional and statewide economic development priorities.
_______________________________________________________________________________
The Center supports the commercialization of research technologies through a variety of programs:
The Center provides mentoring to researchers who believe they have a technology that could serve as the basis
of a new company. The process includes the development of a business presentation for an expert board of
external reviewers.
Commercialization and Entrepreneurial Education seminars and workshops enable researchers to understand
the process of commercializing technologies.
Expert technology reviews provide opportunities for Massachusetts research institutes to have external industry
experts evaluate technologies and give advice regarding their commercial potential.
Technology Forums allow investors and potential corporate partners to meet with companies formed around
technologies developed in Massachusetts research institutes.
www.MTTC.org
www.MassTechPortal.org
MaTTCenter@umassp.edu
twitter.com/MassTTC
8th Annual
Organizers
June 2, 2015
We are motivated to leverage
what is truly unique about MA
“If I stand in the middle of Mass Ave Bridge,
and walk 1 mile in either direction,
I have everything I need to start
a billion dollar life sciences company”
The Massachusetts Life Sciences Start-up Initiative (MALSI) is a collaborative group of
public and private entities that work with emerging biotech and biomed companies. The
prime aim of MALSI is to ensure that every life sciences entrepreneur or researcher who
has a commercializable idea has easy and rapid access to the vast network of organizations
and individuals who can help them realize their dreams. The Massachusetts Technology
Transfer Center, Mass MEDIC, TiE Boston, and MassBio have partnered to present the
Massachusetts Life Sciences Innovation Day.
In case you have any questions, please contact
Massachusetts Technology Transfer Center at mattcenter@umassp.edu
Please join our MALSI Group on LinkedIn.com
8th Annual
In association with
June 2, 2015
Poster Presenters
Anschel Technology, Inc..................................................................................................................... 40
David Anschel, Founder
Aria Neurosciences, Inc...................................................................................................................... 40
Bijan Almassian, President & CEO
BeTH.......................................................................................................................................................... 40
Jason Hill, CEO
Brigham and Women’s Hospital...................................................................................................... 40
Julian Daich, Research Fellow
Harvard Medical School..................................................................................................................... 40
Victor Li, Postdoc fellow
Nathan Palmer, Researcher
David Roberson, Graduate Student
Harvard University............................................................................................................................... 41
Charles Clarke, Researcher
Little Sparrows Technologies........................................................................................................... 41
Donna Brezinski, CEO
Massachusetts Eye and Ear Infirmary............................................................................................ 41
Joseph Ciolino, Assistant Professor
MIFCOR..................................................................................................................................................... 42
Jernej Godec, Co-founder
Sechel Therapeutics, Inc..................................................................................................................... 42
Ephraim Trakhtenberg, Co-founder
Strategia Therapeutics, Inc................................................................................................................ 42
Akinori Hishiya, Director
Tufts University...................................................................................................................................... 42
Clay Bennett, Assistant Professor
University of Massachusetts Medical School............................................................................. 42
Jennifer Broderick, Researcher
Poster Presenters 35
8th Annual
Marie Didiot, Researcher
Neil Marya, Researcher
Jie Song, Associate Professor
Anton Turanov, Researcher
Jianwen Xu, Researcher
Wellumina Health, Inc......................................................................................................................... 44
Peter Tarca, CEO
Worcester Polytechnic Institute...................................................................................................... 44
Sarah Hernandez, PhD Candidate
Wyss Institute for Biologically Inspired Engineering, Harvard University........................ 44
Yevgeny Brudno, Researcher
Wyss Institute for Biologically Inspired Engineering, Harvard University........................ 44
Jae-Won Shin, Postdoctoral Fellow
36 Poster Presenters
June 2, 2015
Anschel Technology, Inc
Presented by:
David Anschel, Founder
danschel@yahoo.com
Poster Title: SightSaverTM
Aria Neurosciences, Inc.
Presented by:
Bijan Almassian, President & CEO
balmassian@arianeurosciences.com
Poster Title: Title Novel Disease Modifying Therapy for Alzheimer’s Disease (AD)
BeTH
Presented by:
Jason Hill, CEO
jason@bethcare.us
Poster Title: BeTH’s Dynamic Prosthetic Liner Reduces Pain for Leg Amputees
Brigham and Women’s Hospital
Presented by:
Julian Daich, Research Fellow
julian.daich@bioimag.com
Poster Title: Magnetically Functionalized Collagen for the Detection of Enzymatic Activity
Harvard Medical School
Presented by:
Victor Li, Postdoc fellow
Victor_li@hms.harvard.edu
Poster Title:
tion
StemCellerant – safe and reliable technology for rapid stem cell differentia-
37
8th Annual
Presented by:
Nathan Palmer, Researcher
nathan_palmer@hms.harvard.edu
Poster Title:
pression
A tool for drug response prediction and drug repositioning using gene ex-
Presented by:
David Roberson, Graduate Student
dprobers@fas.harvard.edu
Poster Title:“Trojan horse” delivery of charged compounds through TRP channels to target
multiple diseases: novel compounds to treat pain, itch, and inflammation
Harvard University
Presented by:
Charles Clarke, Researcher
chrlesc@hotmail.com
Poster Title: Wearable in healthcare
Little Sparrows Technologies
Presented by:
Donna Brezinski, CEO
donna@littlesparrowstech.com
The Bili-Hut™: Portable, high-intensity phototherapy for home treatment of
neonatal jaundice Poster Title:
Massachusetts Eye and Ear Infirmary
Presented by:
Joseph Ciolino, Assistant Professor
Joseph_Ciolino@meei.harvard.edu
Poster Title: Drug-Eluting Contact Lens
June 2, 2015
MIFCOR
Presented by:
Jernej Godec, Co-founder
Godec@fas.harvard.edu
Poster Title: Developing Novel, Protective Therapeutics for Ischemic Disease
Sechel Therapeutics, Inc
Presented by:
Ephraim Trakhtenberg, Co-founder
trakhtenberg@gmail.com
Poster Title: Molecular Therapy for Nerve Regeneration: Focus on the Optic Nerve
Strategia Therapeutics, Inc.
Presented by:
Akinori Hishiya, Director
akinori.hishiya@strategiatx.com
Poster Title:
teins
TAPBOOST Technology: Enhanced Production for Difficult-to-Produce Pro-
Tufts University
Presented by:
Clay Bennett, Assistant Professor
clay.bennett@tufts.edu
Poster Title: New Methodology for Stereoselective Complex Carbohydrate Synthesis
University of Massachusetts Medical School
Presented by:
Jennifer Broderick, Researcher
jennifer.broderick@umassmed.edu
Poster Title:Gene Silencing by Tethering RISC
39
8th Annual
Presented by:
Marie Didiot, Researcher
Marie.didiot@umassmed.edu
Exosome-Mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA
Poster Title:
Presented by:
Neil Marya, Researcher
Neil.marya@umassmemorial.org
Poster Title: The utility of clinical scoring systems in mobile platforms
Presented by:
Jie Song, Associate Professor
Jie.Song@umassmed.edu
Poster Title: A high-performance biodegradable polymer/hydroxyapatite composite for
versatile skeletal tissue engineering applications
Presented by:
Anton Turanov, Researcher
Anton.Turanov@umassmed.edu
Poster Title:
eclampsia
Development of Therapeutic anti-sFLT1 siRNAs for the Treatment of Pre-
Presented by:
Jianwen Xu, Researcher
Jianwen.Xu@umassmed.edu
A versatile hydrogel formulation system combining tunable gelling rate,
degradation rate, excellent mechanical properties with unparalleled compatibility
with therapeutic additives
Poster Title:
June 2, 2015
Wellumina Health, Inc.
Presented by:
Peter Tarca, CEO
ptarca@wellumina.com
Poster Title: Wellumina mHealth Point-of-Care Diagnostic Screening Platform
Worcester Polytechnic Institute
Presented by:
Sarah Hernandez, PhD Candidate
sarah.runge@wpi.edu
Poster Title: Characterization of Pre-cancer Biomarker
Wyss Institute for Biologically Inspired Engineering, Harvard
University
Presented by:
Yevgeny Brudno, Researcher
brudno@fas.harvard.edu
Poster Title: Refillable Drug Delivery Device
Wyss Institute for Biologically Inspired Engineering, Harvard
University
Presented by:
Jae-Won Shin, Postdoctoral Fellow
jwshin@seas.harvard.edu
Poster Title: Optimizing Cell Delivery By Single-Cell Encapsulation In Microgels
41
8th Annual
Innovators’ Marketplace Exhibitors
Life Science Products and Services
Baren-Boym Product Design....................................................................www.baren-boym.com
Boehringer Iingelheim Pharmaceuticals.................................... www.boehringer-ingelheim.com
Catapult Product Development........................................................................... www.catpd.com
CreaGen Chemistry Incubator ................................................www.creagenchemincubator.com
Cummings School of Veterinary Medicine at Tufts University....................... www.cvet.tufts.edu
CuriRx, Inc.......................................................................................................... www.curirx.com
Fisher Scientific....................................................................................... www.thermofisher.com
Integral Biosystems....................................................................... www.integralbiosystems.com
Mansfield Bio-Incubator, Inc................................................................................ www.bioinc.org
Masy BioServices................................................................................................www.masy.com
Mass Innovation Labs, LLC......................................................... www.massinnovationlabs.com
MedChem Partners........................................................................ www.medchempartners.com
Organix, Inc...............................................................................................www.corganixinc.com
Plexus Corp.......................................................................................................www.plexus.com
PPD Laboratories............................................................................................... www.cppdi.com
qPharmetra............................................................................................. www.cqPharmetra.com
Safety Partners, Inc .........................................................................www.safetypartnersinc.com
Toxikon Corporation..........................................................................................www.toxikon.com
Entrepreneurship Support
Massachusetts Life Sciences Center...............................................www.masslifesciences.com
Massachusetts Technology Trasfer Center..................................................www.mattcenter.org
MassBio........................................................................................................... www.massbio.org
MALSI............................................................................. www.linkedin.com/groups?gid=113959
Massachusetts Medical Device Development Center (M2D2)..................... www.uml.edu/m2d2
Harvard Biotechnology Club.................................................................. www.thebiotechclub.org
Boston Life Science Networking...................................................... www.bostonlifescience.com
42 Innovator's Marketplace Exhibitors
June 2, 2015
Harvard Alumni Entrepreneurs........................................ www.harvardalumnientrepreneurs.org
Lemelson-MIT Program................................................................................. web.mit.edu/invent
Life Science Nation .......................................................................... www.lifesciencenation.com
MASS-AWIS.................................................................................................www.mass-awis.org
Massachusetts Biomedical Initiatives....................................................... www.massbiomed.org
Massachusetts Medical Device Development Center (M2D2) .................... www.uml.edu/m2d2
MassMedic................................................................................................www.massmedic.com
Massachusetts Technology Leadership Council................................ www.masstechleaders.org
Massachusetts Technology Collaborative..................................................... www.masstech.org
MassGlobal Partners....................................................................www.massglobalpartners.com
MVVF..................................................................................................................... www.mvvf.org
North Shore InnoVentures...................................................................................... www.nsiv.org
OPEN............................................................................................. www.open-newengland.com
TiE.................................................................................................................www.tie-boston.org
The Bioscience Network............................................................. www.thebiosciencenetwork.org
VentureWell...............................................................................................www.cventurewell.org
WEST............................................................................................................... www.westorg.org
Funding
CIMIT..................................................................................................................... www.cimit.org
Mass Medical Angels.........................................................................www.massmedangels.com
MassChallenge Inc................................................................................www.masschallenge.org
New England Venture Capital Association.............................................www.newenglandvc.org
The Capital Network – TCN...............................................................www.thecapitalnetwork.org
Professional Services
Lathrop & Gage LLP................................................................................. www.lathropgage.com
MintzMintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C................................. www.mintz.com
Pepper Hamilton LLP..................................................................................www.pepperlaw.com
Innovator's Marketplace Exhibitors 43
8th Annual
Notes
44 Innovator's Marketplace Exhibitors

2015_Notebook - The Massachusetts Technology Transfer Center

Transcription

Similar documents

Rally Flyer - The Massachusetts Teachers Association

ConEdison Solutions, Gexa, Pepco Energy 7:30am

Health Justice for Boston Number 2

please click here - VoX International

Event Information

: Al ahram hebdo (journal egyptien) 2007

Giving Back – Don Chiofaro 63

About Clerys: Side Room Function Space

Annual Report FY06 - Phillips Brooks House Association

Fact Sheet